Johnson & Johnson Quarterly Growth and MedTech Outlook

A company update reviews Johnson & Johnson’s sequential growth and performance across pharmaceuticals and medical technology. It also outlines the company’s expectations for cardiac recovery and factors affecting the medtech business.

- Pharmaceuticals: growth in oncology, neuroscience and immunology, including discussion of Stelara exclusivity loss and a new psoriasis product.
- Medical technology: reported growth, cardiac recovery pump expectations and macroeconomic or geopolitical factors.

This overview is for viewers following Johnson & Johnson’s business performance and healthcare-sector developments. It highlights the areas to watch, including the company’s planned cardiac-pump data release, without covering detailed financial results or clinical evidence.